Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2013 Nov 18.

Published in final edited form as: Naunyn Schmiedebergs Arch Pharmacol. 2012 Jan 17;385(5):10.1007/s00210-011-0719-6. doi: 10.1007/s00210-011-0719-6

Radioligand competition experiments with clofarabine, cladribine and fludarabine. The curves in A represent competition for [³H]CCPA binding to A₁ adenosine receptors with clofarabine showing the highest affinity (K_i 248 nM), followed by cladribine (K_i 1,643 nM) and fludarabine (K_i 2,238 nM). In B competition binding of clofarabine to A₁, A_2A, and A₃ receptors using [³H]CCPA, [³H]NECA, and [³H]HEMADO as radioligands, respectively (corresponding K_i values are: 248 nM, 17,500 nM, and 8,280 nM. The shown curves are from single experiments, for data in detail see Table 1.

Radioligand competition experiments with clofarabine, cladribine and fludarabine. The curves in A represent competition for [³H]CCPA binding to A₁ adenosine receptors with clofarabine showing the highest affinity (K_i 248 nM), followed by cladribine (K_i 1,643 nM) and fludarabine (K_i 2,238 nM). In B competition binding of clofarabine to A₁, A_2A, and A₃ receptors using [³H]CCPA, [³H]NECA, and [³H]HEMADO as radioligands, respectively (corresponding K_i values are: 248 nM, 17,500 nM, and 8,280 nM. The shown curves are from single experiments, for data in detail see Table 1.